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Remels AH, Gosker HR, Langen RC, Schols AM. The mechanisms of cachexia
underlying muscle dysfunction in COPD. J Appl Physiol 114: 1253–1262, 2013. First
published September 27, 2012; doi:10.1152/japplphysiol.00790.2012.—Pulmonary ca-
chexia is a prevalent, debilitating, and well-recognized feature of COPD associated
with increased mortality and loss of peripheral and respiratory muscle function. The
exact cause and underlying mechanisms of cachexia in COPD are still poorly
understood. Increasing evidence, however, shows that pathological changes in
intracellular mechanisms of muscle mass maintenance (i.e., protein turnover and
myonuclear turnover) are likely involved. Potential factors triggering alterations in
these mechanisms in COPD include oxidative stress, myostatin, and inflammation.
In addition to muscle wasting, peripheral muscle in COPD is characterized by a
fiber-type shift toward a more type II, glycolytic phenotype and an impaired
oxidative capacity (collectively referred to as an impaired oxidative phenotype).
Atrophied diaphragm muscle in COPD, however, displays an enhanced oxidative
phenotype. Interestingly, intrinsic abnormalities in (lower limb) peripheral muscle
seem more pronounced in either cachectic patients or weight loss-susceptible
emphysema patients, suggesting that muscle wasting and intrinsic changes in
peripheral muscle’s oxidative phenotype are somehow intertwined. In this
manuscript, we will review alterations in mechanisms of muscle mass mainte-
nance in COPD and discuss the involvement of oxidative stress, inflammation,
and myostatin as potential triggers of cachexia. Moreover, we postulate that an
impaired muscle oxidative phenotype in COPD can accelerate the process of
cachexia, as it renders muscle in COPD less energy efficient, thereby contrib-
uting to an energy deficit and weight loss when not dietary compensated.
Furthermore, loss of peripheral muscle oxidative phenotype may increase the
muscle’s susceptibility to inflammation- and oxidative stress-induced muscle
damage and wasting.
COPD; skeletal muscle; cachexia; energy metabolism; muscle mass regulation
CACHEXIA IS A COMPLEX, DEBILITATING metabolic syndrome asso-
ciated with an underlying chronic illness and is characterized
by involuntary and progressive loss of skeletal muscle mass
with variable loss of fat mass (33). Chronic obstructive pul-
monary disease (COPD) is a lung disorder with progressive
airflow obstruction resulting from inflammation and remodel-
ing of the airways, which often includes development of
emphysema. The prevalence of cachexia is high in COPD
(20 – 40% depending on definition and disease stage) and
appears more prevalent in the emphysematous phenotype
(53, 107). Pulmonary cachexia increases mortality and is
associated with poor quality of life and loss of peripheral
and respiratory muscle function (30, 90). Interestingly, stud-
ies in food-restricted animals (52) and in anorexia nervosa
patients (16) show that weight loss per se results in an
emphysema-like pulmonary phenotype highlighting the
complex interrelation between cachexia and pulmonary
function.
The clinical diagnosis of cachexia is traditionally based on
determination of body weight or body mass index (BMI).
However, this approach warrants caution. First, muscle wast-
ing is not only present in underweight COPD patients, but may
also present itself in normal-weight patients with relative
preservation of whole body fat mass or specific accumulation
of visceral fat (37, 103). Therefore, without additional assess-
ment of fat-free mass (FFM), “hidden” loss of muscle mass
may remain undetected. Moreover, FFM index (FFMI) is an
independent determinant of mortality in COPD and, compared
with BMI, is a better predictor of muscle weakness and
impaired exercise capacity (90, 103). Additionally, cachexia is
a process and the time course of weight loss is often not
reported in COPD literature. In this review, we will refer to
patients as underweight (low BMI only), muscle-atrophied
(low FFMI and normal BMI), or cachectic (low FFMI and low
BMI) based on reported body composition (90).
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Muscle wasting in COPD progresses gradually, but likely is
accelerated during acute disease exacerbations. Weight loss
prior to as well as during hospitalization for a COPD exacer-
bation is associated with an increased risk for impaired recov-
ery and hospital readmission (74). Furthermore, loss of FFM
and muscle strength is more frequent and more severe in
repeatedly exacerbating patients (4, 49). A more gradual loss of
muscle and fat mass, on the other hand, appears more prevalent
in advanced disease and in the emphysematous phenotype (32,
53) where cachexia has been associated with increased severity
of emphysema (84).
The observation that FFM wasting can occur with or without
decreases in BMI suggests that different pathophysiological
mechanisms (protein metabolism vs. energy metabolism) may
affect muscle function in pulmonary cachexia. Specifically,
alterations in energy metabolism in COPD appear different
from other chronic wasting diseases and we postulate that these
abnormalities may even accelerate cachexia in COPD. In
addition to peripheral muscle wasting, pulmonary cachexia is
also associated with diaphragm atrophy and weakness, but
intrinsic alterations in energy metabolism in respiratory and
peripheral muscles appear distinct.
MUSCLE MASS MAINTENANCE IN COPD
Muscle wasting in COPD is, at least partly, the result of a
decrease in the size of individual muscle fibers (13, 40).
Whereas peripheral (lower limb) muscle fiber atrophy in
COPD seems selective for the glycolytic type II fibers (40),
diaphragm atrophy is characterized by a more generalized
reduction in the size of all fiber types (14). Interestingly,
malnutrition or nutritional deprivation in animal models also
result in significant diaphragm atrophy and loss of diaphragm
contractile force (26, 39), indicating that malnutrition per se
can lead to diaphragm atrophy.
Muscle mass is determined by the net balance of protein
synthesis and protein breakdown as well as myonuclear loss
and accretion (apoptosis vs. regeneration), as represented in
Fig. 1.
Protein Turnover
In COPD, on a whole body level, increased protein turnover
has been reported (29, 51). It is, however, currently unclear
whether cachexia is associated with changes in muscle protein
synthesis. While one group reported decreased muscle protein
synthesis in underweight emphysema patients (68), others, at
whole body level, showed no difference or even an increase in
protein synthesis in cachectic patients compared with controls
or non-cachectic patients (51, 87). No data exist on synthesis
and degradation rates of muscle-specific proteins, albeit that
(whole body) myofibrillar protein degradation was found to be
increased in underweight patients compared with controls and
normal-weight patients (87). Indirect evidence for increased
muscle-protein degradation was shown in emphysematous and
underweight COPD patients based on increased circulatory
levels of methylhistidine, a product of muscle protein break-
down (99). Additionally, increased levels of pseudo-uridine (a
proposed marker for cellular protein breakdown) in urine of
COPD patients correlated inversely with FFM (10).
Protein Degradation Pathways
Although several proteolytic systems in skeletal muscle can
degrade contractile proteins, the ubiquitin-proteasome system
(UPS) is considered the main proteolytic system involved in









































Fig. 1. Schematic representation of the trig-
gers and underlying mechanism of cachexia
in COPD. Myostatin (MSTN), peroxisome
proliferator-activated receptor gamma coacti-
vator 1 (PGC1), Forkhead box O (FOXO),
nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-B), muscle atrophy
F-box (Atrogin-1), muscle-specific ring fin-
ger 1 (MuRF1), Insulin-like growth factor-1
(IGF-1), mechanogrowth factor (MGF), serine/
threonine protein kinase AKT (AKT), glycogen
synthase kinase 3 (GSK3), eIF4E-binding
protein 1 (4E-BP1), ribosomal protein S6 ki-
nase (P70S6K), ubiquitin-proteasome sys-
tem (UPS), mitogen-activated protein kinase
(MAPK), extracellular signal-regulated kinase
(ERK), c-Jun N-terminal kinase (JNK).
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muscle-specific RING finger protein 1 (MuRF1), regulated by
fork-head transcription factors FOXO-1 and 3, are key players
in UPS-dependent protein degradation (38).
Atrogin-1 mRNA and protein levels, not MuRF1, were
found to be increased in peripheral muscle of muscle-atrophied
COPD patients compared with controls (59, 73). In cachectic
patients, atrogin-1 mRNA and protein as well as MuRF1
mRNA and total protein ubiquitination were increased com-
pared with controls (27, 34). Moreover, muscle atrogin-1
protein content, not MuRF1 protein, was specifically increased
in cachectic COPD patients compared with non-cachectic pa-
tients (105). In line with these observations, FOXO-1 and
FOXO-3 mRNA levels were shown to be increased, compared
with controls, in peripheral muscle of cachectic and muscle-
atrophied COPD patients. In addition, muscle FOXO-1 nuclear
content was found to be increased, compared with controls, in
cachectic patients (21, 27, 34). A drawback for interpretation
of data on FOXO, however, is that Doucet et al. (27) only
reported nuclear, not total FOXO-1 protein levels, and did not
investigate phosphorylation status of FOXO-1. In addition to
increased atrogin mRNA and protein, muscle Nedd4 (another
E3 ubiquitin-protein ligase) protein levels were also found
increased in muscle-atrophied patients with severe COPD com-
pared with controls (73).
Recently, increased atrogin-1 protein expression in muscle-
atrophied COPD patients (FFMI: 17.5  0.5 vs. 19.8  0.5 in
controls) was associated with increased mitogen-activated pro-
tein kinase (MAPK) activation (p38, ERK 1/2, and JNK) which
inversely correlated with mid-thigh cross-sectional area (59).
In contrast, compared with controls, others found no differ-
ences in MAPK activation in muscle-atrophied COPD patients
(FFMI: 16.1  2.2), although it must be noted that the control
group had a relatively low FFMI (17.2  2.2) as well, which
may have masked potential differences (86). Additionally,
Fermoselle et al. (34) found no differences in MAPK protein
levels between controls, cachectic, and non-cachectic patients,
which must, however, be interpreted with caution because
phosphorylated MAPK protein levels would have been more
informative in terms of activation of these pathways (34).
Importantly, convincing evidence for a direct role of MAPK in
the induction of E3 ligases in conditions of muscle atrophy is
lacking. In line with well-described diaphragm atrophy in
COPD, protein degradation seems enhanced in the diaphragm
(e.g., increased proteasome activity and atrogin-1 mRNA ex-
pression) as recently reviewed by Caron et al. (13). Collec-
tively, activation of the UPS has been consistently shown in
peripheral (lower limb) muscle of both muscle-wasted patients
and cachectic patients, whereas data on muscle UPS activation
in muscle of normal-weight or underweight patients are lack-
ing.
Protein Synthesis Pathways
The insulin-like growth factor-1 (IGF-1)-Akt signaling cas-
cade is an essential pathway for muscle anabolism and hyper-
trophy. Circulating IGF-1 levels were unaltered in mild, mod-
erate, and severe COPD compared with controls (72) and in
cachectic vs. non-cachectic patients (22). However, muscle
IGF-1 protein was decreased in cachectic COPD patients
compared with non-cachectic patients (105), and serum and
muscle IGF-1 levels were lower in acute exacerbating COPD
patients compared with controls (19, 54).
Interestingly, in addition to increased expression of E3
ligases, increased activation of Akt was observed in peripheral
muscle of cachectic patients vs. controls (27, 105). Down-
stream of Akt, the expression levels of 4E-BP1, P70S6K, and
GSK-3 were increased specifically in cachectic patients com-
pared with non-cachectic patients (27). The net result on
protein synthesis remains difficult to interpret as these media-
tors have opposing effects on mRNA translation (see Fig. 1).
Moreover, interpretation is also limited because the ratio of
phosphorylated over total protein (which was lacking) is most
informative in terms of pathway activation. Nevertheless, ac-
tivation of muscle hypertrophic signaling pathways in the
presence of cachexia could be interpreted as a futile attempt to
restore muscle mass. In muscle-atrophied patients on the other
hand, Akt phosphorylation was unaltered while muscle IGF-1
mRNA levels were increased compared with controls (60, 73).
No data exist on protein synthesis pathways in COPD dia-
phragm. In summary, although circulating IGF-1 levels appear
to be unaltered, downstream Akt signaling is activated com-
pared with controls in lower limb muscle of cachectic patients
but not in muscle-atrophied patients.
Myonuclear Turnover
The concept of a “myonuclear domain” (a given nucleus can
only control a certain volume of cytoplasm) implies that a
myofiber upon loss or gain of volume will have to adapt its
nuclear content. Therefore, loss of muscle mass may not only
involve changes in protein metabolism, but also involves
changes in loss and accretion of myonuclei in muscle fibers.
Loss of myonuclei is predominantly controlled by apoptotic
events. Accretion of myonuclei is the result of fusion of
mononuclear myoblasts with adjacent myofibers. These cells
arise from locally residing “satellite cells” and subsequently
differentiate under the influence of myogenic differentiation
factors.
Apoptotic Mechanisms
Literature regarding muscle cell apoptosis in COPD is still
controversial. Some groups reported increased muscle cell
apoptosis (as reflected by DNA fragmentation) in underweight
patients compared with controls and normal-weight patients (3,
7), whereas others showed no differences in active caspase-3
(as a marker for apoptosis) in muscle-atrophied patients com-
pared with controls (42). Increased apoptosis has been ob-
served in diaphragm of animal models of emphysema or
pulmonary inflammation (23, 47) and recently also in COPD
diaphragm (7).
Regeneration Pathways
Impaired muscle regeneration may contribute to muscle
atrophy in COPD, as it inhibits myonuclear accretion of myo-
fibers, limiting their capacity for (re)growth. In this context,
several groups have assessed, in muscle of COPD patients,
mRNA and protein expression levels of constituents of key
pathways involved in muscle regeneration. Muscle mRNA
levels of myogenic differentiation factors Myf5, and myogenin
and MyoD protein levels were unaltered in muscle-atrophied
COPD patients compared with controls (73). However, muscle
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myogenin protein expression was lower in cachectic patients
compared with controls, and MyoD protein was found signif-
icantly lower in cachectic vs. non-cachectic COPD patients
(34, 105). In addition, patients undergoing an acute exacerba-
tion displayed reduced muscular levels of MyoD protein com-
pared with healthy controls (19). This data point toward de-
creased expression levels of myogenic differentiation factors,
which are essential for muscle regenerative capacity, specifi-
cally in skeletal muscle of cachectic COPD patients. Satel-
lite cell activation, increased MGF, and embryonic myosin
heavy chain (MyHC) mRNA expression have been shown in
diaphragm of COPD patients, suggesting an ongoing regen-
erative process (69). In addition, animal models of emphy-
sema revealed a decreased diaphragmatic content of MyoD
protein (23).
TRIGGERS OF CACHEXIA IN COPD
An inactive lifestyle is a common characteristic of COPD
and may have profound effects on peripheral skeletal muscle
function. However, because disuse preferentially affects type I
fibers, type II fiber atrophy in COPD reflects pathological
mechanisms additional to physical inactivity, of which oxida-
tive/nitrosative stress, myostatin, and inflammation have been
investigated as putative catabolic triggers (Fig. 1).
Oxidative/Nitrosative Stress
Reactive oxygen species (ROS) result from mitochondrial
O2 consumption or from other oxidant producing systems in
the muscle as, e.g., the xanthine oxidase system. In addition to
their direct oxidizing effects, ROS can give rise to reactive
nitrogen species (RNS) by interacting with nitric oxide (NO).
Oxidative/nitrosative stress can induce cell damage and cell
death, impair myogenic differentiation (57), activate the UPS,
and block protein synthesis (75), all of which may contribute to
muscle atrophy.
An imbalance between the production of reactive species
and antioxidant capacity leads to oxidative/nitrosative stress. In
this regard, mitochondrial H2O2 production at rest (76) and
exercise-induced xanthine oxidase activity were increased sig-
nificantly in muscle of normal-weight patients compared with
healthy subjects (24). In addition, basal antioxidant levels were
reduced in peripheral musculature and circulation of emphy-
sematous COPD patients compared with controls and in ca-
chectic patients vs. non-cachectic patients (31, 101). Also,
exercise-induced increases in antioxidant enzymes were atten-
uated or inhibited in underweight and normal-weight patients
compared with controls (77, 78). Collectively, this results in
increased systemic (circulation) and local (muscle) oxida-
tive/nitrosative stress in COPD at rest and after acute exercise
(34, 111).
Systemic and local oxidative stress in COPD patients cor-
related negatively with FFM and muscle strength, suggesting a
link between oxidative stress and loss of muscle mass (8, 100).
Furthermore, cachectic COPD patients exhibited greater mus-
cle and systemic oxidative/nitrosative stress at rest and after
exercise compared with non-cachectic patients and controls (8,
101). In line with these data, mitochondrial ROS production
was found significantly greater in cachectic patients compared
with non-cachectic patients and was associated with enhanced
UPS activity and protein ubiquitination (34). In contrast, Fer-
moselle et al. (34) showed increased oxidative stress markers
regardless of body composition, whereas only cachectic pa-
tients exhibited additional activation of proteolytic systems and
atrophy of type II muscle fibers. Similar to peripheral muscle,
increased oxidative stress is observed in COPD diaphragm,
which may contribute to atrophy (6, 64).
Myostatin
Myostatin can induce muscle atrophy through inhibition of
myoblast proliferation (by inhibiting MyoD), increasing UPS
activity, and inhibiting anabolic signaling through the IGF/Akt
pathway.
Myostatin mRNA expression in (lower limb) muscle was
found increased in muscle-atrophied COPD patients compared
with controls (73) and inversely correlated with quadriceps
strength and endurance in patients (108). Myostatin protein
levels in muscle, however, were unchanged in cachectic vs.
non-cachectic patients (105). As myostatin produced in muscle
is processed and excreted from the tissue (48), serum myostatin
protein may serve as a biomarker. Indeed, circulatory myosta-
tin levels were elevated in COPD patients compared with
controls and correlated inversely with muscle mass (in men
only) (50). It is unknown if and by which exact mechanisms
myostatin might contribute to muscle atrophy in COPD. How-
ever, Plant et al. (73) associated increased muscle myostatin
mRNA levels in muscle-atrophied patients compared with
controls with increased UPS activity. Summarized, the avail-
able data suggest that muscle myostatin expression is elevated
in muscle-atrophied and cachectic COPD patients compared
with controls.
An overview of described alterations in protein degradation/
synthesis and regeneration/apoptosis pathways in muscle of
COPD patients is provided in Table 1. Comparisons between
normal- and underweight patients and controls are excluded
because of a lack of data in literature.
Inflammation
Inflammatory mediators have long been implicated in mus-
cle atrophy and cachexia (81, 92). In particular, tumor necrosis
factor- (TNF-) was originally designated “cachectin” in
recognition of its catabolic actions. Historically, Beutler and
Cerami (13a) were the first to describe a link between TNF-
and a cachectic phenotype characterized by anorexia and weak-
ness. Follow-up studies demonstrated that experimental ani-
mals lose weight and muscle mass and display muscle weak-
ness when treated with TNF- or exposed to interventions that
elevate endogenous TNF- (e.g., sepsis or tumor implantation)
(35, 66). Both acute and chronic models of inflammation result
in muscle atrophy (35, 56). Currently, a causal role for inflam-
matory cytokines, especially TNF-, has been established in
several in vivo and in vitro models of inflammation-induced
muscle atrophy (92, 95). Mechanisms by which TNF- may
mediate muscle atrophy include UPS activation and enhanced
proteolysis, but also inhibition of protein synthesis and block-
ade of myogenic differentiation and muscle regenerative po-
tential (56, 81). In particular, the inflammatory signaling path-
way nuclear factor B (NF-B) has been causally implicated in
(inflammation-induced) loss of muscle mass in experimental
models in vivo and in vitro. NF-B activation stimulates the
proteasomal machinery and leads to significant loss of muscle
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mass, whereas NF-B inhibition protects against the develop-
ment of muscle atrophy in several experimental models (11,
62). Interestingly, NF-B activation is required for the transi-
tion of systemic inflammation to muscle atrophy in a model of
pulmonary inflammation (55).
COPD is often associated with a chronic low-grade inflam-
matory state with increased circulating levels of TNF-, solu-
ble TNF- receptors, C-reactive protein (CRP), and interleukin
(IL)-1 and IL-6 being reported (70). Although systemic
inflammation is not present in all patients, a significant subset
of patients displays persistent systemic inflammation that re-
lates to increased mortality (1). In addition, acute exacerbations
result in enhanced pulmonary and systemic inflammation and
the presence of systemic inflammation is associated with an
increased exacerbation frequency (1, 94). The exact relation-
ship of systemic inflammation with the process of muscle
wasting in COPD, however, is unclear because of a lack of
longitudinal data. In addition, the presence of local inflamma-
tion in skeletal muscle of COPD patients is controversial.
Some studies showed increased levels of TNF- in the periph-
eral muscle of selected COPD patients (67, 82), whereas others
failed to reproduce these results (9, 19). To date, these apparent
discrepancies remain unexplained but differences in study
population characteristics in terms of disease severity and body
composition may play a role. However, regardless of TNF-
expression in muscle, data regarding activation of the nuclear
factor B (NF-B) pathway in COPD skeletal muscle does
suggest an increased inflammatory state of peripheral muscle
tissue in this disorder. Indeed, increased muscle NF-B acti-
vation was shown in severely underweight patients and in
cachectic patients and muscle-atrophied patients compared
with controls (2, 34, 73) but also in cachectic patients com-
pared with non-cachectic patients (105). Recently, increased
NF-B activation in quadriceps muscle of cachectic COPD
patients compared with controls was also found to correlate
with total muscle protein ubiquitination (34). These authors,
however, only assessed total, not nuclear, protein levels of
RelA in muscle (transcriptional active NF-B subunit), which
is not informative with regard to NF-B activation. Collec-
tively, although scarcely available, data do point toward in-
creased NF-B activation in peripheral skeletal muscle of
COPD patients.
Some groups have investigated inflammatory cell infiltration
in muscle tissue of COPD patients as a potential source for
inflammatory mediators affecting the muscle. Compared with
controls, however, no differences were found in muscle inflam-
matory cell infiltration in normal-weight COPD patients or in
patients with evident muscle atrophy (42, 72). In contrast,
Barreiro et al. (7) did show increased numbers of inflammatory
cells in muscle tissue from normal-weight COPD patients
compared with controls. These authors, however, reported very
low counts for inflammatory cells in muscle of both patients
and controls which could underlie apparent discrepancies be-
tween studies.
In COPD, elevated circulating levels of TNF- and its
soluble receptors have been associated with acute weight loss
(25) and a reduced lean mass (28). Also, systemic inflamma-
tion was more pronounced in cachectic patients compared with
non-cachectic patients (101) and patients who fail to gain
weight in response to nutritional support are characterized by
high circulating levels of soluble TNF- receptors (17). How-
ever, no reports are available addressing via which mecha-
nisms (increased degradation, impaired protein synthesis, or
impairment of regeneration) chronic inflammation and NF-B
activation contribute to muscle wasting in COPD.
MUSCLE METABOLISM IN CACHEXIA IN COPD
Although loss of muscle mass results in decreased strength,
intrinsic muscle metabolic abnormalities impair muscle endur-
ance, thereby further contributing to muscle dysfunction in
COPD. In peripheral muscle, a fiber-type shift (I-II) toward a
higher proportion of glycolytic fibers in COPD has been
associated with disease severity (44) and appeared aggravated
in emphysematous patients (43, 89).
Table 1. Protein synthesis/degradation and














MuRF1 mRNA 59,73 127 ND
MuRF1 protein 59,73 34 105
Atrogin mRNA 159,73 127 ND
Atrogin protein 159 127,34 1105
Nedd4 protein 173 ND ND
FoxO mRNA 121 127 ND
FoxO protein ND 127,34 ND
Poly-ubiquitinated protein 159 134 ND
Protein Synthesis
Muscle IGF-1 mRNA 160 ND ND
Muscle IGF-1 protein ND ND 2105
Circulating IGF-1 ND 27 22
P-Akt/Total Akt 73 127 1105
Apoptosis
TUNEL 42 ND ND
Caspase-3 42 ND ND
Regeneration
Myf 5mRNA 73 ND ND
Myogenin mRNA 73 ND ND
Myogenin protein ND 234 ND
MyoD mRNA ND ND ND
MyoD protein 73 ND 2105
Myostatin
Muscle myostatin mRNA 173 ND ND
Muscle myostatin protein ND 134 105
Oxidative Stress
Muscle protein oxidation 159 134 1101,8
Muscle anti-oxidants ND 134 134,8231
Inflammation
Muscle TNF- 21167 3429182 105182
Muscle NF-B activity 173 134 1105
MuRF1, muscle-specific RING finger protein 1; Nedd4, neuronal precursor
cell-expressed developmentally downregulated 4; FoxO, fork-head transcrip-
tion factor; IGF-1, insulin growth factor 1; Akt, protein kinase B; TUNEL,
terminal uridine nick-end labeling; Myf5, myogenic factor 5; MyoD, myogenic
differentiation antigen; TNF-, tumor necrosis factor ; NF-B, nuclear factor
B; ND, not determined. Numbers indicate relevant references.
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Oxidative Metabolism
In addition to a fiber-type shift, COPD peripheral muscle has
a decreased content of high-energy phosphates (ATP and
phosphocreatine) at rest with a faster drop and slower recovery
upon exercise, independent of nutritional status, indicative of
an impaired oxidative metabolism (46, 91). Indeed, activity
levels of mitochondrial oxidative enzymes (Krebs cycle and
-oxidation) were reduced in peripheral musculature of stable
COPD patients, with decreases tending to be more severe in the
emphysematous patient (20, 42, 63). In concordance, decreased
numbers of mitochondria, but normal intrinsic mitochondrial
function, were shown in lower limb muscle of normal-weight
COPD patients compared with controls (41, 76). Intriguingly,
mitochondrial function was particularly impaired in cachectic
patients compared with non-cachectic patients (79). Moreover,
cachectic patients in this study had a lower diffusing capacity
of the lung for carbon monoxide (suggestive of emphysema)
and a reduced endurance capacity compared with non-cachec-
tic patients even when corrected for FFM (79). Collectively,
muscle oxidative capacity and fiber-type composition will be
referred to as oxidative phenotype. Peroxisome proliferator-
activated receptors (PPAR)- and - and their coactivator
PPAR coactivator-1 (PGC-1) together with mitochondrial
transcription factor-A promote mitochondrial biogenesis and a
slow fiber-type muscle phenotype. In line with their known
function, protein and mRNA levels of these constituents were
decreased in COPD muscle compared with controls, which was
particularly pronounced in cachectic patients (82, 83). These
data show that muscle oxidative phenotype and its molecular
regulation by the PGC/PPAR signaling pathway is impaired in
COPD, which is most pronounced in cachectic patients.
Glycolytic Metabolism
In addition to an impaired oxidative phenotype, increased
glycolytic metabolism has been observed in peripheral muscle of
COPD patients at rest and after exercise (45, 46, 88). Also,
exercise-induced lactate production (i.e., enhanced anaerobic gly-
colysis) occurred earlier in cachectic patients compared with
non-cachectic patients (79). In line with these studies, whole body
glucose production was increased in normal-weight COPD pa-
tients upon exercise, whereas underweight patients already dis-
played increased glucose production at rest (36). Additionally,
normal-weight COPD patients displayed a faster drop in muscle
PH in response to mild exercise, and glycogen utilization and
lactate accumulation required a lower work load and time to occur
in normal-weight patients compared with controls (88). Similar to
impairments in muscle oxidative phenotype, enhancement of
glycolytic metabolism is more pronounced in cachectic patients.
In line with this notion, stimulation of mitochondrial oxidative
metabolism attenuated exercise-induced lactate production in
COPD, suggesting that impairments in muscle oxidative metab-
olism increase the muscle’s reliance on glycolysis as a source of
energy generation (12).
Unlike peripheral muscle, an increased proportion of type I
fibers was observed in diaphragm of emphysematous COPD
patients compared with controls. Moreover, capillary density,
mitochondrial function, and oxidative enzyme activities were
enhanced in diaphragm of normal-weight COPD patients com-
pared with controls, reflecting an endurance training-like effect
potentially resulting from the increased work of breathing (13).
Collectively, diaphragm and peripheral muscles show similar
abnormalities with regard to atrophy, proteasome activity, oxida-
tive stress, and regenerative signaling, and these abnormalities
may originate systemically. However, differences between intrin-
sic abnormalities in oxidative phenotype in peripheral vs. dia-
phragmatic muscle in COPD suggest that local factors, such as
activity level, likely participate in the muscle modifications ob-
served in COPD.
ACCELERATORS OF CACHEXIA IN COPD
The fact that many of the impairments in (peripheral) COPD
muscle oxidative phenotype seem more pronounced in either
cachectic patients or weight loss-susceptible emphysematous
patients (53, 79) suggests a relationship between muscle wast-
ing and intrinsic changes in the muscle’s oxidative profile.
Here we postulate that loss of skeletal muscle oxidative phe-
notype could potentially accelerate the cachexia process in
COPD, as outlined in Fig. 1.
Energy Metabolism
Weight loss occurs when energy expenditure exceeds energy
intake. Decreased dietary intake is sometimes present in
COPD, in particular during acute exacerbations, and has been
related to hypoxia, systemic inflammation, and elevated levels
of the appetite-regulating hormone leptin (adjusted for fat
mass) (18, 102). However, anorexia is not the primary cause of
weight loss in clinically stable disease (15). First, severe COPD
patients with a low BMI displayed an increased, not decreased,
caloric intake (84). Moreover, although the normal response to
(semi)starvation is reducing resting energy expenditure (EE),
severe COPD patients often displayed an increased resting EE
even when corrected for FFM (51). Collectively, this suggests
a hypermetabolic state that may contribute to weight loss if
caloric demand is not fully met.
In addition to an increased resting EE, activity-induced EE is
increased in COPD that, compared with resting EE, contributes
most to elevated total daily EE (93). Increases in activity-
induced EE in COPD may be explained by a decreased me-
chanical efficiency (the chemical conversion of energy to
mechanical work) during lower limb exercise (5, 85). Recently,
a higher ATP cost of muscle contraction in COPD patients vs.
controls was found, which further supports the lower mechan-
ical efficiency hypothesis (58).
Other factors that may well contribute to increases in both
resting and activity-induced EE in COPD include impairments in
the muscle’s oxidative phenotype, increased reliance on glycolytic
metabolism, and I-II fiber-type shifting (i.e., metabolic ineffi-
ciency). In addition, the oxygen cost of breathing is higher
(attributable to airway obstruction and hyperinflation) in COPD,
which may also increase EE (5). Moreover, protein turnover is a
major determinant of EE (110), and whole body protein turnover
has been shown to be increased in COPD, which correlated with
increased resting EE and loss of FFM (51, 87).
Summarized, metabolic inefficiency, attributable to impair-
ments in muscle oxidative phenotype, may lead to a decreased
mechanical efficiency and increased EE resulting in an energy
deficit that subsequently contributes to a wasting phenotype. This
is supported by a study showing that mild muscle-specific over-
expression of PGC-1, a key regulator of muscle oxidative
capacity that is decreased in COPD muscle, protects against
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aging-associated activation of degradation pathways involved in
muscle atrophy (109). In this context, it can be speculated that
diaphragmatic muscle in COPD may be relatively protected
against atrophy because of its enhanced oxidative phenotype.
Oxidative Stress and Inflammation
Oxidative/nitrosative stress and inflammation can be consid-
ered as not mutually exclusive processes that can act as
potential accelerators of cachexia. Indeed, inflammatory cyto-
kines can induce oxidative stress (80), which is a known
mechanism leading to muscle damage and wasting (75), but
can also directly induce proteosomal degradation of muscle
proteins. This most likely is mediated through activation of the
classical NF-B pathway (56, 81), which has been shown to be
activated in skeletal muscle of COPD patients (2).
In addition, we previously showed that TNF- can induce a
shift in MyHC composition toward more fast glycolytic (type II)
MyHC proportion (82). Whether or not induced by inflammation,
a shift in fiber type composition toward a more glycolytic, type II
fiber proportion in COPD may contribute to the process of muscle
atrophy. First, as type II fibers are more sensitive to atrophy-
inducing stimuli (96), a shift toward a higher proportion of
glycolytic fibers may increase the susceptibility of the muscle to
inflammation-induced and oxidative stress-induced damage.
Moreover, it has been shown that mitochondria from glycolytic
type II fibers release significantly more ROS compared with
mitochondria from oxidative type I fibers (71). This implies that a
shift in fiber-type composition toward a higher proportion of type
II fibers may contribute to increased oxidative stress and damage
to muscle proteins. Also, loss of muscle oxidative phenotype,
whether or not induced by inflammatory cytokines and classical
NF-B activation, can contribute significantly to metabolic inef-
ficiency, which, as described above, may also contribute to wast-
ing. Interestingly, TNF- potently impaired the oxidative pheno-
type of cultured myotubes and COPD patients with elevated
mRNA levels of muscle TNF- displayed decreased expression
of oxidative genes, impaired PGC-1/PPAR expression and a
cachectic phenotype compared with COPD patients with normal
muscle TNF- levels (82), suggesting a role for TNF- in loss of
muscle oxidative phenotype in COPD.
In light of these observations and the fact that the fiber-type
shift (43, 89), abnormalities in muscle oxidative capacity (79,
82), and levels of oxidative stress (101) appear to be aggra-
vated in cachectic and/or emphysematous COPD patients it can
be postulated that an impaired muscle oxidative phenotype as
well as the presence of inflammation and oxidative stress could
be considered as potential accelerators of cachexia in COPD.
THERAPEUTIC INTERVENTIONS
Protein Synthesis and Regeneration
Several studies in COPD demonstrated that therapeutic inter-
ventions aimed at increasing muscle mass induce signaling events
involved in protein synthesis. Indeed, increases in leg lean mass
and muscle fiber size after either training, testosterone supplemen-
tation, or electrical stimulation were paralleled by increases in
muscle IGF-1 protein and mRNA levels and increased expression
of the load-sensitive splice variant of IGF-1:MGF (mechano-
growth factor) and activation of the protein synthesis machinery
(61, 104, 106). Only one study addressed the muscle anabolic
response in cachectic COPD patients upon pulmonary rehabilita-
tion, which on the basis of muscle IGF-I expression levels,
appeared present but attenuated compared with noncachectic
patients (105). In addition, studies have shown that physical
exercise training in COPD patients activates pathways involved in
muscle regeneration. Normal-weight COPD patients and controls
display similar training-induced increments in peak work rate and
muscle expression of MyoD mRNA, MyoD protein, and myoge-
nin mRNA (61, 106), suggesting that COPD patients retain the
capacity to induce peripheral muscle adaptations upon training.
Interestingly, rehabilitation-induced increases in MyoD mRNA
occurred both in cachectic and noncachectic patients, whereas
MyoD protein only increased in noncachectic patients (105).
Moreover, fiber size increased in both groups, but significantly
less in cachectic than in noncachectic patients, suggesting that
cachectic COPD patients may only partially retain the capacity for
peripheral muscle remodeling in response to rehabilitation/exer-
cise training.
Protein Degradation
Pulmonary rehabilitation decreased muscle atrogin-1 and
MuRF1 expression in noncachectic patients, whereas expres-
sion levels were increased in skeletal muscle of cachectic
patients in response to rehabilitation (105). Also, Lewis et al.
(61) demonstrated a small reduction in myostatin mRNA levels
upon pulmonary rehabilitation in combination with testoster-
one in normal-weight COPD patients (61). Furthermore, quad-
riceps myostatin mRNA and protein expression were reduced
in noncachectic and normal-weight patients upon resistance
training and pulmonary rehabilitation, respectively, which,
interestingly, was not observed in cachectic patients (98, 105).
Collectively, current therapeutic interventions aimed at in-
creasing muscle mass activate protein synthesis and regenera-
tive signaling and decrease myostatin and UPS E3-ligase
expression in skeletal muscle of normal-weight and noncachec-
tic patients. These effects were significantly attenuated or even
absent or in cachectic patients.
FUTURE PERSPECTIVES
Many studies include COPD patients with advanced disease
(GOLD III-IV). However, to adequately investigate the time
course and development of muscle atrophy and aberrations in
muscle oxidative phenotype in COPD, longitudinal studies in
less-severe COPD patients are important. This will increase in-
sights in the pathophysiology of cachexia and will pave the way
for developing novel tailored therapeutic strategies. Also, recent
data identified that, in addition to activated protein degradation
pathways, protein synthesis signaling via Akt is activated in
skeletal muscle of cachectic COPD patients. Future research is
needed to unravel whether protein synthesis is indeed activated in
peripheral muscle of cachectic COPD patients. Additionally, to
date, only one study compared pulmonary rehabilitation-induced
muscle adaptations in cachectic patients vs. non-cachectic patients
(105). These authors reported that rehabilitation-induced muscle
adaptations with respect to activation of signaling pathways in-
volved in protein synthesis and regeneration appear attenuated in
cachectic patients compared with noncachectic patients. In light of
these data, more studies are needed to adequately address whether
cachectic patients retain the capacity for peripheral muscle remod-
eling upon rehabilitation. Furthermore, to shed more light on the
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involvement of apoptosis and impaired regeneration in develop-
ment of muscle atrophy in COPD, more studies are needed to
adequately characterize alterations in muscle apoptotic and regen-
erative pathways in muscle-atrophied and cachectic patients but
also in less severe normal-weight and underweight patients.
CONCLUSION
Our understanding of the mechanisms underlying cachexia and
subsequent muscle dysfunction in COPD has increased signifi-
cantly. Importantly, in addition to BMI, determination of FFMI is
crucial to adequately detect muscle wasting and diagnose ca-
chexia in COPD. Strikingly, upon adequate stratification based on
body composition, there is an apparent relationship between loss
of muscle mass and intrinsic muscle abnormalities in COPD.
Indeed, cachectic patients display more severe abnormalities in
muscle oxidative phenotype, increased oxidative stress, UPS ac-
tivation, and impaired regenerative signaling compared with non-
cachectic patients and muscle-wasted patients. Data with regard to
these parameters in normal-weight or underweight patients with-
out significant muscle atrophy or cachexia is often lacking. On the
basis of available data however, it can be speculated that loss of
peripheral muscle oxidative phenotype may act as an accelerator
of cachexia in COPD, a process in which inflammation and
oxidative stress may play important roles.
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